ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.

Alex C Spyropoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.